Gilead’s Twice-Annual Sunlenca Posts Zero Infection Rate In PrEP Trial

 
• By Joseph Haas
  
HIV prep
Gilead is working to add a twice-annual injectable option for HIV PrEP • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D